Literature DB >> 8749640

Treatment of cerebral Aspergillosis with itraconazole: do high doses improve the prognosis?

C Sánchez1, E Mauri, D Dalmau, S Quintana, A Aparicio, J Garau.   

Abstract

We describe a 72-year-old woman with chronic asthma who presented with cerebral abscesses due to Aspergillus fumigatus after she received treatment with corticosteroids. Therapy with high-dose itraconazole (800 mg/d for 5 months, followed by 400 mg/d for an additional 4.5 months) resulted in complete resolution of all lesions. Serum concentrations of the drug ranged from 2 micrograms/mL to 30 micrograms/mL. Review of 20 cases of cerebral aspergillosis that were treated with itraconazole revealed that three of the four patients who received high doses (800 mg/d in the adults) of the drug responded favorably, while only two of the 16 patients who received a dose of 400 mg/d were cured. The use of high-dose itraconazole appears to be justified for high-risk patients with cerebral aspergillosis for whom conventional therapy has failed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8749640     DOI: 10.1093/clinids/21.6.1485

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  8 in total

1.  Reflections on the approach to treatment of a mycologic disaster.

Authors:  David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2013-02-05       Impact factor: 5.191

2.  Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth.

Authors:  James Kim; Jean Y Tang; Ruoyu Gong; Jynho Kim; John J Lee; Karl V Clemons; Curtis R Chong; Kris S Chang; Mark Fereshteh; Dale Gardner; Tannishtha Reya; Jun O Liu; Ervin H Epstein; David A Stevens; Philip A Beachy
Journal:  Cancer Cell       Date:  2010-04-13       Impact factor: 31.743

3.  Cerebral aspergillosis in the critically ill: two cases of successful medical treatment.

Authors:  Stephan Ehrmann; Frédéric Bastides; Valérie Gissot; Emmanuelle Mercier; Pascal Magro; Eric Bailly; Annick Legras
Journal:  Intensive Care Med       Date:  2005-03-22       Impact factor: 17.440

4.  Necessary and sufficient role for T helper cells to prevent fungal dissemination in allergic lung disease.

Authors:  Paul C Porter; Luz Roberts; Anna Fields; Morgan Knight; Yuping Qian; George L Delclos; Shuhua Han; Farrah Kheradmand; David B Corry
Journal:  Infect Immun       Date:  2011-08-29       Impact factor: 3.441

5.  Aspergillus meningitis: diagnosis by non-culture-based microbiological methods and management.

Authors:  P E Verweij; K Brinkman; H P Kremer; B J Kullberg; J F Meis
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

Review 6.  CNS aspergillosis: recognition, diagnosis and management.

Authors:  Markus Ruhnke; Grzegorz Kofla; Kirsten Otto; Stefan Schwartz
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

7.  Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent.

Authors:  Pan Pantziarka; Vidula Sukhatme; Gauthier Bouche; Lydie Meheus; Vikas P Sukhatme
Journal:  Ecancermedicalscience       Date:  2015-04-15

8.  CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)-Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Authors:  M Schmidt-Hieber; G Silling; E Schalk; W Heinz; J Panse; O Penack; M Christopeit; D Buchheidt; U Meyding-Lamadé; S Hähnel; H H Wolf; M Ruhnke; S Schwartz; G Maschmeyer
Journal:  Ann Oncol       Date:  2016-04-06       Impact factor: 32.976

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.